Start Date
November 30, 2016
Primary Completion Date
August 30, 2018
Study Completion Date
August 30, 2018
Molecularly Tailored Second Line Therapy
This trial is designed to assess the efficacy of MTT vs. SOC therapy as second-line therapy in patients with metastatic pancreatic cancer.
Standard of Care Second Line Therapy
Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Collaborators (3)
Thomas Jefferson University
OTHER
Sinai Health System
OTHER
Virginia Mason Hospital/Medical Center
OTHER
Cedars-Sinai Medical Center
OTHER
George Mason University
OTHER
Caris Life Sciences
INDUSTRY
Theranostics Health, Inc
UNKNOWN
Guardant Health, Inc.
INDUSTRY
Companion Diagnostics, Inc.
UNKNOWN
Georgetown University
OTHER